Partners

Lynn McKinley-Grant, MD, FAAD details what you need to remember when diagnosing and treating psoriasis in patients of color.

New biologic therapy tralokinumab, a human monoclonal antibody targeting IL-13, is under FDA review for the treatment of atopic dermatitis.

Patients often describe seeking alternatives and adjuncts to care for the treatment of their atopic dermatitis. The literature has explored some of the potential in these options.

Phototherapy continues to be a mainstay of psoriasis treatment. Dr Gelfand highlights recommendations for phototherapy administration and patient discussions during the COVID-19 pandemic.

The time away from clinic due to the pandemic has left many with time to contemplate current affairs and their dermatology practice. Sarah Patton, MSHS, PA-C, reflects on how her life and career has changed over the course of 4 months.

In an interview with The Dermatologist, Julie Harper, MD, discussed ways dermatologists can be more proactive in their treatment of rosacea.

While much of research is to test the clinical efficacy and safety of drugs, these posters from the American Academy of Dermatology Virtual Meeting Experience 2020 focused on physician decision-making and evaluation, patient characteristics, and disease severity of eczema.

Kristian Reich, MD, PhD, discussed a therapeutic breakthrough with bimekizumab, a novel biologic in development that inhibits IL-17F in addition to IL-17A.

The evolving pathogenesis and various phenotypic presentations of atopic dermatitis (AD) can guide research to important discoveries in immunotherapy and future therapies, highlighting a positive future in the treatment of AD.

The Dermatologist spoke with investigators behind two prominent international registries dedicated to better understanding how concomitant psoriasis and COVID-19 can affect patient care and outcomes now and in the future.